+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Binge-eating Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

  • PDF Icon

    Report

  • 190 Pages
  • January 2024
  • Region: Global
  • TechSci Research
  • ID: 5938674
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global Binge-eating Disorder Treatment Market was valued at USD 571.32 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028, reaching USD 859.26 million. Binge-eating disorder (BED) is a prevalent and severe eating disorder characterized by recurring episodes of consuming large quantities of food, often accompanied by a lack of control. This mental health condition affects millions of individuals worldwide, making it a significant concern for both public health and healthcare providers. As awareness of BED increases and its diagnosis becomes more precise, the global market for BED treatment has witnessed substantial growth. Binge-eating disorder is not just about overeating; it's a complex mental health condition with numerous psychological, social, and physical consequences. Those suffering from BED often feel intense guilt, shame, and distress, which can exacerbate the disorder and affect their overall quality of life. As the world becomes more conscious of mental health issues, there's a growing need for effective BED treatments.

Increased awareness about BED and its effects has led to more individuals seeking diagnosis and treatment. This has driven the demand for BED therapies and interventions. The ongoing advocacy for mental health awareness and the reduction of stigmas surrounding eating disorders have played a crucial role in driving the BED treatment market. The development of medications specifically designed for BED treatment has been a significant contributor to market growth. Some of these medications have shown promise in reducing binge-eating episodes. Various therapeutic approaches, including cognitive-behavioral therapy and dialectical behavior therapy, have proven effective in treating BED. The demand for therapy services has consequently risen.

Key Market Drivers

Prevalence of Binge-eating Disorder is Driving the Global Binge-eating Disorder Treatment Market

Over the last few decades, there has been a notable increase in the prevalence of binge-eating disorders across the globe. This surge in cases can be attributed to several factors, including increased awareness and better diagnostic criteria. Additionally, changing societal norms, lifestyle, and the increasing prevalence of obesity have contributed to the growing numbers of individuals suffering from Binge-eating Disorder. The impact of binge-eating disorder extends far beyond the individual, affecting their physical and mental health, relationships, and overall quality of life. The surge in Binge-eating disorder cases has led to a significant demand for effective treatment options. As a result, the global Binge-eating Disorder Treatment Market has experienced substantial growth. This market encompasses a range of treatment approaches, including psychotherapy, medication, self-help strategies, and more. The aim of these treatments is to help individuals with Binge-eating disorder gain control over their eating behaviours, improve their mental well-being, and reduce the risk of associated health issues, such as diabetes, heart disease, and obesity.

Cognitive-behavioural therapy (CBT) has shown to be one of the most effective treatments for Binge-eating disorder. It helps individuals identify the triggers and thought patterns that lead to binge-eating episodes and develop healthier coping strategies. In some cases, healthcare professionals may prescribe medications to manage Binge-eating disorder symptoms. Selective serotonin reuptake inhibitors (SSRIs) and antiepileptic drugs have shown promise in reducing the frequency of binge-eating episodes. Self-help books, online resources, and support groups have gained popularity as accessible and cost-effective tools for individuals with Binge-eating disorder. These resources empower individuals to take control of their condition and seek help. Healthcare providers may recommend changes in diet and exercise routines to manage BED symptoms, especially for those with comorbid obesity.

Greater Awareness is Driving the Global Binge-eating Disorder Treatment Market

Awareness of binge-eating disorder has been steadily growing over the past decade. Organizations, advocacy groups, and healthcare professionals have made significant efforts to raise awareness about BED. These initiatives focus on educating the public, healthcare providers, and policymakers about the severity of the disorder and the importance of early diagnosis and treatment. High-profile cases and media attention to BED have contributed to increased public awareness. Documentaries, news stories, and feature films often shine a light on the struggles faced by those with the disorder, helping to break down stigmas. Ongoing research into the causes and treatment of BED have helped to underscore its legitimacy as a serious mental health issue. This research has also led to the development of more effective treatment options.

The rise in awareness has had a direct impact on the global market for binge-eating disorder treatment. As more individuals seek help and professionals diagnose the condition accurately, the demand for treatment has surged. The pharmaceutical industry has responded to the growing demand for BED treatment with the development of medications specifically designed to target binge-eating behavior. These drugs can help reduce the frequency and severity of binge episodes, offering hope for individuals struggling with the disorder. Cognitive-behavioral therapy (CBT) and dialectical behavior therapy (DBT) have emerged as effective treatments for BED. As awareness of these evidence-based therapies spreads, more individuals are seeking the help of mental health professionals, further driving market growth. The rise of telehealth and digital health platforms has made it easier for individuals to access BED treatment, especially in underserved areas. Virtual therapy sessions and mobile apps have made treatment more accessible and convenient. The growth of online support communities and forums has connected individuals with BED to a network of people who understand their struggles. These platforms offer valuable peer support and resources to aid in recovery.

Key Market Challenges

Stigma and Awareness

One of the primary challenges in the BED treatment market is the persistence of stigma surrounding eating disorders, including BED. Many individuals suffering from BED do not seek help due to fear of judgment or misunderstanding of their condition. This lack of awareness not only delays diagnosis and treatment but also limits the market's potential for growth. Efforts to educate the public and healthcare professionals about BED are essential. This includes challenging the misconception that BED is simply a lack of self-control rather than a complex mental health issue. Overcoming stigma remains a significant obstacle in increasing patient engagement in treatment and driving market expansion.

Diagnosis and Screening

BED often goes undiagnosed or misdiagnosed as other eating disorders or mental health conditions, such as bulimia or depression. To effectively treat BED, early and accurate diagnosis is crucial. However, healthcare providers face challenges in implementing standardized screening and diagnostic protocols. Improving the accuracy of diagnosis through screening tools and training for healthcare professionals is a pressing issue. The development of effective diagnostic tools can enhance the treatment market by ensuring that individuals receive appropriate care.

Treatment Options

The variety of treatment options for BED remains somewhat limited compared to other eating disorders. While cognitive-behavioral therapy (CBT) has shown effectiveness in treating BED, not all patients respond well to this approach. Pharmaceutical treatments are also being explored, but the approval and market adoption of such drugs face regulatory hurdles and challenges related to safety and efficacy. Research into alternative treatment modalities, personalized therapy plans, and innovative medications is crucial to provide tailored approaches to individuals with BED. Expanding the range of available treatments is a key factor in addressing the challenges faced by the BED treatment market.

Access to Care

Access to appropriate care for BED remains a significant challenge in many regions. Financial barriers, lack of specialized treatment centers, and inadequate insurance coverage often prevent individuals from seeking the help they need. This results in underutilization of existing treatment options and hampers market growth. Addressing these challenges involves expanding access to affordable and evidence-based treatment options, increasing mental health parity in insurance policies, and developing a network of healthcare providers trained in BED treatment.

Research and Data Gaps

There is still much to learn about BED, its causes, and the most effective treatment approaches. The BED treatment market requires a robust foundation of research and data to guide advancements. Gaps in our understanding of the condition, including its genetic, neurobiological, and psychosocial underpinnings, hinder the development of targeted therapies. Investment in research and data collection is critical for overcoming these challenges. Collaboration between researchers, healthcare professionals, and pharmaceutical companies is needed to advance our knowledge of BED and develop more effective treatments.

Key Market Trends

Technological Advancements

Technological advancements have greatly improved the ability to diagnose binge-eating disorders. Machine learning algorithms and artificial intelligence (AI) tools can analyze patient data, such as medical history, food diaries, and even voice and text analysis, to detect patterns indicative of BED. These tools can assist healthcare professionals in making earlier and more accurate diagnoses, which is crucial for effective intervention. Telemedicine has become a crucial component of healthcare, especially in the context of mental health conditions like BED. Patients can now connect with therapists and healthcare providers remotely, ensuring regular check-ins and consistent support. Telemedicine apps and platforms also enable the monitoring of food intake, emotions, and progress over time. This has been a game-changer, as it allows patients to receive help from the comfort of their own homes, reducing the barriers to seeking treatment. Digital therapeutics, often in the form of smartphone apps, are revolutionizing the treatment of binge-eating disorder. These applications provide patients with tools for tracking their eating habits, setting goals, and practicing mindfulness. They often employ cognitive-behavioural therapy (CBT) techniques, which are highly effective in treating BED. Digital therapeutics not only enhance the efficacy of treatment but also improve patient engagement and adherence to therapy.

Wearable devices, such as smartwatches and fitness trackers, have integrated features that enable individuals to monitor their physical activity, heart rate, and sleep patterns. These devices can be instrumental in helping individuals with binge-eating disorder by fostering healthier lifestyles. By promoting regular exercise and improved sleep quality, they contribute to better overall well-being and can indirectly aid in the treatment process. The collection and analysis of big data have opened up new possibilities for understanding and treating BED. By analysing large datasets, researchers and healthcare providers can identify trends, risk factors, and potential treatment responses. This enables more personalized treatment plans tailored to each patient's unique needs, increasing the chances of success.

Segmental Insights

Type Insights

Based on the category of Type, Antidepressants emerged as the dominant player in the global market for Binge-eating Disorder Treatment in 2022. Antidepressants are a class of medications that have been found to be effective in treating binge-eating disorder. These drugs were initially developed to alleviate symptoms of depression, but their impact on BED is now widely recognized. Specifically, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have shown promise in reducing the frequency and severity of binge-eating episodes. Antidepressants target the brain's neurotransmitters, such as serotonin and norepinephrine, which are associated with mood regulation. By improving mood and reducing symptoms of depression and anxiety, these medications can reduce the emotional triggers that lead to binge-eating. Some antidepressants, like bupropion, can reduce appetite, making it easier for patients to control their food intake and resist the urge to binge. Antidepressants can enhance a patient's ability to resist impulsive behavior, which is often a significant factor in binge-eating episodes.

Distribution Channel Insights

The offline segment is projected to experience rapid growth during the forecast period. Offline distribution channels have historically been the cornerstone of the Binge-eating Disorder treatment market, with healthcare professionals, clinics, and hospitals playing a crucial role in patient assessment and treatment. Offline distribution channels allow for a patient-centric approach to treatment, ensuring that the individual's unique needs and circumstances are at the forefront of the treatment plan. Seeking treatment for a mental health disorder can still carry stigma in many societies. Offline channels often provide a discreet and confidential setting for individuals to receive treatment without fear of judgment or disclosure.

Regional Insights

North America emerged as the dominant player in the global Binge-eating Disorder Treatment market in 2022, holding the largest market share in terms of value. North America, particularly the United States and Canada, has some of the highest prevalence rates of binge-eating disorder in the world. This has led to a greater demand for effective treatments and a more extensive market for pharmaceutical companies and treatment providers.

Report Scope

In this report, the Global Binge-eating Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Binge-eating Disorder Treatment Market, By Type:

  • Antidepressants
  • Anticonvulsants
  • Stimulants
  • Others

Binge-eating Disorder Treatment Market, By Distribution Channel:

  • Offline
  • Online

Binge-eating Disorder Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Binge-eating Disorder Treatment Market.

Available Customizations:

The analyst offers customization according to specific needs, along with the already-given market data of the Global Binge-eating Disorder Treatment market report.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Binge-eating Disorder Treatment Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Antidepressants, Anticonvulsants, Stimulants, Others)
4.2.2. By Distribution Channel (Offline, Online)
4.2.3. By Region
4.2.4. By Company (2022)
4.3. Market Map
4.3.1. By Type
4.3.2. By Distribution Channel
4.3.3. By Region
5. Asia Pacific Binge-eating Disorder Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Distribution Channel
5.2.3. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Binge-eating Disorder Treatment Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Distribution Channel
5.3.2. India Binge-eating Disorder Treatment Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Distribution Channel
5.3.3. Australia Binge-eating Disorder Treatment Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Distribution Channel
5.3.4. Japan Binge-eating Disorder Treatment Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Distribution Channel
5.3.5. South Korea Binge-eating Disorder Treatment Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Distribution Channel
6. Europe Binge-eating Disorder Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. Europe: Country Analysis
6.3.1. France Binge-eating Disorder Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Distribution Channel
6.3.2. Germany Binge-eating Disorder Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Distribution Channel
6.3.3. Spain Binge-eating Disorder Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Distribution Channel
6.3.4. Italy Binge-eating Disorder Treatment Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Distribution Channel
6.3.5. United Kingdom Binge-eating Disorder Treatment Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Distribution Channel
7. North America Binge-eating Disorder Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States Binge-eating Disorder Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Distribution Channel
7.3.2. Mexico Binge-eating Disorder Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Distribution Channel
7.3.3. Canada Binge-eating Disorder Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Distribution Channel
8. South America Binge-eating Disorder Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Binge-eating Disorder Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Distribution Channel
8.3.2. Argentina Binge-eating Disorder Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Distribution Channel
8.3.3. Colombia Binge-eating Disorder Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Distribution Channel
9. Middle East and Africa Binge-eating Disorder Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Binge-eating Disorder Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Distribution Channel
9.3.2. Saudi Arabia Binge-eating Disorder Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Distribution Channel
9.3.3. UAE Binge-eating Disorder Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Binge-eating Disorder Treatment Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Viatris Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Product & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Johnson and Johnson
14.3. Lupin Ltd.
14.4. Omeros Corp.
14.5. Pyramid Healthcare Inc.
14.6. Sumitomo Pharma Co. Ltd.
14.7. Takeda Pharmaceutical Co. Ltd.
14.8. Eli Lilly and Co
14.9. Tonix Pharmaceuticals Holding Corp.
14.10. Tryp Therapeutics Inc.
15. Strategic Recommendations16. About Us & Disclaimer

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Viatris Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Omeros Corp.
  • Pyramid Healthcare Inc.
  • Sumitomo Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Co
  • Tonix Pharmaceuticals Holding Corp.
  • Tryp Therapeutics Inc.

Table Information